Moderate to Severe Airflow Limitation

Classification of Severity Based on FEV1

The British Thoracic Society guidelines classify an FEV1 of 46% as "moderate COPD", defined as FEV1 between 40-59% of predicted value 1
The European Respiratory Society classifies an FEV1 of 46% as "severe" airflow limitation, defined as FEV1 <50% predicted 2
This level of lung function impairment is associated with significant symptoms and may lead to work difficulties and intermittent hospital admissions 1
Patients with this level of FEV1 impairment typically present with respiratory complaints 1

This degree of airflow limitation correlates with reduced quality of life and increased likelihood of exacerbations 1, 2
Patients with FEV1 <50% may have reduced exercise capacity and are at higher risk for respiratory complications 1

FEV1 alone is not sufficient for diagnosis - the FEV1/FVC ratio must also be evaluated to confirm obstructive disease 3
An FEV1/FVC ratio <70% in conjunction with reduced FEV1 confirms obstructive airway disease 3
Bronchodilator testing should be performed to assess for reversibility, which may help distinguish between asthma and COPD, according to the European Respiratory Journal 3

Patients with FEV1 of 46% require comprehensive treatment, which may include bronchodilators and possibly inhaled corticosteroids, as recommended by the British Thoracic Society and European Respiratory Society 1, 2
Pulmonary rehabilitation should be considered for patients with this level of impairment 1
These patients should be monitored for exacerbations and complications of COPD 1
For surgical candidates, an FEV1 <50% requires careful preoperative assessment, including possible exercise testing, as stated in the Annals of Oncology 5

Relying solely on FEV1 without considering the FEV1/FVC ratio can lead to misdiagnosis, as noted in the European Respiratory Journal 3
Different guidelines use different thresholds for severity classification, leading to potential confusion in interpretation, according to the British Thoracic Society and European Respiratory Society 1, 2